HSPA1A and neoplasm: In addition to advancing to phase II–III clinical trials of the HSP70-based vaccines, another pressing issue that needs attention is how to validate the efficacy of these two therapeutic strategies targeting HSP70 in different types of cancers, given that HSP70 has a dual role in tumor progression.